Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Ezekowitz

Showing results (141-150 of 187) with videos related to

Pageof 19
Sort By:
European Heart Journal|February 6, 2016
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2Hans-Christoph Diener, James Aisenberg, Jack Ansell, et al.
European Heart Journal|February 6, 2016
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1Hans-Christoph Diener, James Aisenberg, Jack Ansell, et al.
Heart (British Cardiac Society)|June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practiceKyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
American Heart Journal|April 29, 2014
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversionMichael D Ezekowitz, Riccardo Cappato, Allan L Klein, et al.
Lancet (London, England)|September 4, 2016
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trialAndreas Goette, Jose L Merino, Michael D Ezekowitz, et al.
Circulation|January 29, 2019
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic SurgeonsCraig T January, L Samuel Wann, Hugh Calkins, et al.
JAMA Cardiology|July 4, 2019
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial FibrillationSean D Pokorney, DaJuanicia N Holmes, Laine Thomas, et al.
Journal of the American College of Cardiology|February 1, 2019
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm SocietyCraig T January, L Samuel Wann, Hugh Calkins, et al.
Circulation|January 26, 2011
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart AssociationPaul A Heidenreich, Justin G Trogdon, Olga A Khavjou, et al.
Heart Rhythm|February 1, 2019
2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society, Craig T January, L Samuel Wann, et al.
Pageof 19

Showing results (141-150 of 187) with videos related to

Sort By:
Pageof 19
European Heart Journal|February 6, 2016
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2Hans-Christoph Diener, James Aisenberg, Jack Ansell, et al.
European Heart Journal|February 6, 2016
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1Hans-Christoph Diener, James Aisenberg, Jack Ansell, et al.
Heart (British Cardiac Society)|June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practiceKyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
American Heart Journal|April 29, 2014
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversionMichael D Ezekowitz, Riccardo Cappato, Allan L Klein, et al.
Lancet (London, England)|September 4, 2016
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trialAndreas Goette, Jose L Merino, Michael D Ezekowitz, et al.
Circulation|January 29, 2019
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic SurgeonsCraig T January, L Samuel Wann, Hugh Calkins, et al.
JAMA Cardiology|July 4, 2019
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial FibrillationSean D Pokorney, DaJuanicia N Holmes, Laine Thomas, et al.
Journal of the American College of Cardiology|February 1, 2019
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm SocietyCraig T January, L Samuel Wann, Hugh Calkins, et al.
Circulation|January 26, 2011
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart AssociationPaul A Heidenreich, Justin G Trogdon, Olga A Khavjou, et al.
Heart Rhythm|February 1, 2019
2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society, Craig T January, L Samuel Wann, et al.
Pageof 19